Praxis Precision Medicines, Inc.NASDAQ: PRAX

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Praxis Precision Medicines, Inc. via GlobeNewswire

Summary by 6ix AI

On November 2, 2026, the Compensation Committee of the Board of Directors of Praxis Precision Medicines, a biopharmaceutical company developing therapies for central nervous system disorders, granted restricted stock unit awards (rights to receive shares later) covering an aggregate of 23,219 shares of common stock to fifty-nine new non-executive employees.

Key details

  • The awards were made under the Praxis Precision Medicines, Inc. 2024 Inducement Plan as inducements material to the employees' entering into employment with Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4), a listing rule of the Nasdaq stock exchange.
  • The 2024 Inducement Plan is used only for equity awards to people who were not previously Praxis employees, or who are joining after a genuine period of non-employment.

What’s still pending

  • The restricted stock units will vest in four equal annual installments, subject to each employee's continued employment with Praxis on each vesting date.

6ix AI wrote this summary from the release below and checked it against the release.

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 23,219 shares of its common stock to fifty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

View original source (GlobeNewswire)Praxis Precision Medicines, Inc. on 6ix

Earlier from Praxis Precision Medicines

Later from Praxis Precision Medicines

All Praxis Precision Medicines news releases